Dermatitis News

Patients with moderate to severe atopic dermatitis treated with amlitelimab showed both clinical and biomarker improvements, including in patients who withdrew from treatment, according to phase 2b trial results.

Infection rates were lower following longer dupilumab treatment exposure in children with moderate to severe atopic dermatitis, according to a study.

BOSTON — Roflumilast cream improved signs and symptoms of atopic dermatitis, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Allergists should resist the pressure to test children with atopic dermatitis for food allergies, David R. Stukus, MD, FACAAI, said during the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Upadacitinib exhibited efficacy and a favorable benefit-risk profile for the long-term treatment of moderate to severe atopic dermatitis in adolescents, according to a study.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis, according to a study.

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.